Breast cancer stem cells: Multiple capacities in tumor metastasis

Cancer Letters

Volumn 349, Issue 1, 2014, Pages 1-7

  Geng, Shao Qing ^a   Alexandrou, Aris T ^b   Li, Jian Jian ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cancer stem cells; EMT; HER2; Metastasis; Therapeutic resistance

Indexed keywords

BIOLOGICAL MARKER; CD47 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SIGNAL REGULATORY PROTEIN ALPHA; UNCLASSIFIED DRUG; TUMOR MARKER;

BREAST CANCER; CANCER STEM CELL; CELL INTERACTION; CELL RENEWAL; CELLULAR IMMUNITY; CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE EVASION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BREAST NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84901019637     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.036     Document Type: Review

References (103)

1. Waterworth A. Introducing the concept of breast cancer stem cells. Breast Cancer Res. 2004, 6:53-54.
2. Ponti D., Zaffaroni N., Capelli C., Daidone M.G. Breast cancer stem cells: an overview. Eur. J. Cancer 2006, 42:1219-1224.
3. Duru N., Fan M., Candas D., Menaa C., Liu H.C., Nantajit D., Wen Y., Xiao K., Eldridge A., Chromy B.A., Li S., Spitz D.R., Lam K.S., Wicha M.S., Li J.J. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin. Cancer Res. 2012, 18:6634-6647.
4. Gjerdrum C., Tiron C., Hoiby T., Stefansson I., Haugen H., Sandal T., Collett K., Li S., McCormack E., Gjertsen B.T., Micklem D.R., Akslen L.A., Glackin C., Lorens J.B. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. USA 2010, 107:1124-1129.
5. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
6. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
7. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T., Gu K., Shah V., Pei L., Zarbo R.J., McCauley L., Shi S., Chen S., Wang C.Y. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 2007, 13:62-69.
8. Al-Hajj M., Becker M.W., Wicha M., Weissman I., Clarke M.F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 2004, 14:43-47.
9. Wicha M.S. Cancer stem cells and metastasis: lethal seeds. Clin. Cancer Res. 2006, 12:5606-5607.
10. Clarke M.F. A self-renewal assay for cancer stem cells. Cancer Chemother. Pharmacol. 2005, 56(Suppl. 1):64-68.
11. Moncharmont C., Levy A., Gilormini M., Bertrand G., Chargari C., Alphonse G., Ardail D., Rodriguez-Lafrasse C., Magne N. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 2012, 322:139-147.
12. Chen D., Bhat-Nakshatri P., Goswami C., Badve S., Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res. 2013, 73:5821-5833.
13. Li L., Neaves W.B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006, 66:4553-4557.
14. Frosina G. DNA repair in normal and cancer stem cells, with special reference to the central nervous system. Curr. Med. Chem. 2009, 16:854-866.
15. Lou H., Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007, 26:1357-1360.
16. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
17. Qian Z., Fernald A.A., Godley L.A., Larson R.A., Le Beau M.M. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 2002, 99:14925-14930.
18. Wicha M.S. Breast cancer stem cells: the other side of the story. Stem Cell Rev. 2007, 3:110-112. discussion 113.
19. Vlashi E., Kim K., Lagadec C., Donna L.D., McDonald J.T., Eghbali M., Sayre J.W., Stefani E., McBride W., Pajonk F. In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl. Cancer Inst. 2009, 101:350-359.
20. Cho R.W., Wang X., Diehn M., Shedden K., Chen G.Y., Sherlock G., Gurney A., Lewicki J., Clarke M.F. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem cells 2008, 26:364-371.
21. Sell S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 2004, 51:1-28.
22. Korkaya H., Wicha M.S. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013, 73:3489-3493.
23. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
24. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
25. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
26. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., Fiocco R., Foroni C., Dimeco F., Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64:7011-7021.
27. Singh S.K., Clarke I.D., Hide T., Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene 2004, 23:7267-7273.
28. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
29. Sun B., Roh K.H., Park J.R., Lee S.R., Park S.B., Jung J.W., Kang S.K., Lee Y.S., Kang K.S. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy 2009, 11:289-298. 281 p following 298.
30. Ljujic B., Milovanovic M., Volarevic V., Murray B., Bugarski D., Przyborski S., Arsenijevic N., Lukic M.L., Stojkovic M. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci. Rep. 2013, 3:2298.
31. El-Haibi C.P., Bell G.W., Zhang J., Collmann A.Y., Wood D., Scherber C.M., Csizmadia E., Mariani O., Zhu C., Campagne A., Toner M., Bhatia S.N., Irimia D., Vincent-Salomon A., Karnoub A.E. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl. Acad. Sci. USA 2012, 109:17460-17465.
32. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., Jung Y., Dontu G., Taichman R., Wicha M.S. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71:614-624.
33. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
34. Van Pham P., Vu N.B., Duong T.T., Nguyen T.T., Truong N.H., Phan N.L., Vuong T.G., Pham V.Q., Nguyen H.M., Nguyen K.T., Nguyen N.T., Nguyen K.G., Khat L.T., Van Le D., Truong K.D., Phan N.K. Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. Onco. Targets Therapy 2012, 5:77-84.
35. Liu H., Patel M.R., Prescher J.A., Patsialou A., Qian D., Lin J., Wen S., Chang Y.F., Bachmann M.H., Shimono Y., Dalerba P., Adorno M., Lobo N., Bueno J., Dirbas F.M., Goswami S., Somlo G., Condeelis J., Contag C.H., Gambhir S.S., Clarke M.F. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci USA 2010, 107:18115-18120.
36. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., Chieco P., Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
37. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006, 66:1883-1890. discussion 1895-1886.
38. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., Guan J.L., Dontu G., Wicha M.S. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120:485-497.
39. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
40. Hiscox S., Parr C., Nakamura T., Matsumoto K., Mansel R.E., Jiang W.G. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. Breast Cancer Res. Treat. 2000, 59:245-254.
41. LeBedis C., Chen K., Fallavollita L., Boutros T., Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int. J. Cancer 2002, 100:2-8.
42. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002, 62:5476-5484.
43. Singer C.F., Kronsteiner N., Marton E., Kubista M., Cullen K.J., Hirtenlehner K., Seifert M., Kubista E. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res. Treat. 2002, 72:69-77.
44. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., Sawyers C.L., Weissman I.L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351:657-667.
45. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
46. Abrahamsson A.E., Geron I., Gotlib J., Dao K.H., Barroga C.F., Newton I.G., Giles F.J., Durocher J., Creusot R.S., Karimi M., Jones C., Zehnder J.L., Keating A., Negrin R.S., Weissman I.L., Jamieson C.H. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. USA 2009, 106:3925-3929.
47. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
48. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., Munchhof M., VanArsdale T., Beachy P.A., Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
49. Dierks C., Beigi R., Guo G.R., Zirlik K., Stegert M.R., Manley P., Trussell C., Schmitt-Graeff A., Landwerlin K., Veelken H., Warmuth M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
50. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.K., Sato A., Satyal S., Wang X., Clarke M.F., Lewicki J., Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
51. Baccelli I., Schneeweiss A., Riethdorf S., Stenzinger A., Schillert A., Vogel V., Klein C., Saini M., Bauerle T., Wallwiener M., Holland-Letz T., Hofner T., Sprick M., Scharpff M., Marme F., Sinn H.P., Pantel K., Weichert W., Trumpp A. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31:539-544.
52. Magbanua M.J., Sosa E.V., Roy R., Eisenbud L.E., Scott J.H., Olshen A., Pinkel D., Rugo H.S., Park J.W. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013, 73:30-40.
53. Molnar B., Ladanyi A., Tanko L., Sreter L., Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin. Cancer Res. 2001, 7:4080-4085.
54. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G., Uhr J.W., Terstappen L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
55. Theodoropoulos P.A., Polioudaki H., Agelaki S., Kallergi G., Saridaki Z., Mavroudis D., Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010, 288:99-106.
56. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massague J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
57. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
58. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
59. Bonnomet A., Syne L., Brysse A., Feyereisen E., Thompson E.W., Noel A., Foidart J.M., Birembaut P., Polette M., Gilles C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2012, 31:3741-3753.
60. Bhat-Nakshatri P., Goswami C.P., Badve S., Sledge G.W., Nakshatri H. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci. rep. 2013, 3:2530.
61. Wang K.H., Kao A.P., Lin T.C., Chang C.C., Kuo T.C. Promotion of epithelial-mesenchymal transition and tumor growth by 17beta-estradiol in an ER(+)/HER2(+) cell line derived from human breast epithelial stem cells. Biotechnol. Appl. Biochem. 2012, 59:262-267.
62. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106:13820-13825.
63. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
64. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., Quraishi A.A., Tawakkol N., D'Angelo R., Paulson A.K., Chung S., Luther T., Paholak H.J., Liu S., Hassan K.A., Zen Q., Clouthier S.G., Wicha M.S. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012.
65. Angelucci C., Maulucci G., Lama G., Proietti G., Colabianchi A., Papi M., Maiorana A., De Spirito M., Micera A., Balzamino O.B., Di Leone A., Masetti R., Sica G. Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness. PLoS ONE 2012, 7:e50804.
66. Vuoriluoto K., Haugen H., Kiviluoto S., Mpindi J.P., Nevo J., Gjerdrum C., Tiron C., Lorens J.B., Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011, 30:1436-1448.
67. Yamashita N., Tokunaga E., Kitao H., Hisamatsu Y., Taketani K., Akiyoshi S., Okada S., Aishima S., Morita M., Maehara Y. Vimentin as a poor prognostic factor for triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 2013, 139:739-746.
68. Tilghman S.L., Townley I., Zhong Q., Carriere P.P., Zou J., Llopis S.D., Preyan L.C., Williams C.C., Skripnikova E., Bratton M.R., Zhang Q., Wang G. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol. Cell Proteomics 2013, 12:2440-2455.
69. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
70. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., Hallett M., Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
71. Winkler I.G., Barbier V., Nowlan B., Jacobsen R.N., Forristal C.E., Patton J.T., Magnani J.L., Levesque J.P. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat. Med. 2012, 18:1651-1657.
72. Illing A., Liu P., Ostermay S., Schilling A., de Haan G., Krust A., Amling M., Chambon P., Schinke T., Tuckermann J.P. Estradiol increases hematopoietic stem and progenitor cells independent of its actions on bone. Haematologica 2012, 97:1131-1135.
73. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
74. Shiozawa Y., Pienta K.J., Taichman R.S. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin. Cancer Res. 2011, 17:5553-5558.
75. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., Garcia-Santos G., Ghajar C., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
76. Hardee M.E., Marciscano A.E., Medina-Ramirez C.M., Zagzag D., Narayana A., Lonning S.M., Barcellos-Hoff M.H. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res. 2012, 72:4119-4129.
77. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
78. Hoffman R.M. Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised niche. Breast Cancer Res. 2013, 15:310.
79. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massague J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17:867-874.
80. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
81. Li Z., Xia L., Lee M.L., Khaletskiy A., Wang J., Wong J.Y.C., Li J.J. Effector genes altered in MCF-7 human breast cancer cells after exposure to fractionated ionizing radiation. Radiat. Res. 2001, 155:543-553.
82. Magnifico A., Albano L., Campaner S., Delia D., Castiglioni F., Gasparini P., Sozzi G., Fontanella E., Menard S., Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 2009, 15:2010-2021.
83. Malik F., Korkaya H., Clouthier S.G., Wicha M.S. Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle 2012, 11:2780-2781.
84. Cao N., Li S., Wang Z., Ahmed K.M., Degnan M.E., Fan M., Dynlacht J.R., Li J.J. NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat. Res. 2009, 171:9-21.
85. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., Quraishi A.A., Tawakkol N., D'Angelo R., Paulson A.K., Chung S., Luther T., Paholak H.J., Liu S., Hassan K.A., Zen Q., Clouthier S.G., Wicha M.S. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012, 47:570-584.
86. Lee C.G., Das B., Lin T.L., Grimes C., Zhang X., Lavezzi T., Huang L., Cole J., Yau L., Li L. A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. Br. J. Haematol. 2012, 158:79-90.
87. Ricardo S., Vieira A.F., Gerhard R., Leitao D., Pinto R., Cameselle-Teijeiro J.F., Milanezi F., Schmitt F., Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 2011, 64:937-946.
88. Draffin J.E., McFarlane S., Hill A., Johnston P.G., Waugh D.J. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res. 2004, 64:5702-5711.
89. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., Saad Z., Doig G.S., Chambers A.F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 1998, 79:502-508.
90. Weber G.F., Ashkar S., Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc. Assoc. Am. Phys. 1997, 109:1-9.
91. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., Beider K., Avniel S., Kasem S., Galun E., Peled A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004, 18:1240-1242.
92. Chao M.P., Majeti R., Weissman I.L. Programmed cell removal: a new obstacle in the road to developing cancer. Nat. Rev. Cancer 2012, 12:58-67.
93. Lamagna C., Aurrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 2006, 80:705-713.
94. Fang L.Y., Izumi K., Lai K.P., Liang L., Li L., Miyamoto H., Lin W.J., Chang C. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013, 73:5633-5646.
95. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117:1137-1146.
96. Jaiswal S., Chao M.P., Majeti R., Weissman I.L. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010, 31:212-219.
97. Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 1992, 13:265-270.
98. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
99. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., van Rooijen N., Weissman I.L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
100. Chan K.S., Espinosa I., Chao M., Wong D., Ailles L., Diehn M., Gill H., Presti J., Chang H.Y., van de Rijn M., Shortliffe L., Weissman I.L. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2009, 106:14016-14021.
101. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., Wang J., Contreras-Trujillo H., Martin R., Cohen J.D., Lovelace P., Scheeren F.A., Chao M.P., Weiskopf K., Tang C., Volkmer A.K., Naik T.J., Storm T.A., Mosley A.R., Edris B., Schmid S.M., Sun C.K., Chua M.S., Murillo O., Rajendran P., Cha A.C., Chin R.K., Kim D., Adorno M., Raveh T., Tseng D., Jaiswal S., Enger P.O., Steinberg G.K., Li G., So S.K., Majeti R., Harsh G.R., van de Rijn M., Teng N.N., Sunwoo J.B., Alizadeh A.A., Clarke M.F., Weissman I.L. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 2012, 109:6662-6667.
102. Kim D., Wang J., Willingham S.B., Martin R., Wernig G., Weissman I.L. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012, 26:2538-2545.
103. Tseng D., Volkmer J.P., Willingham S.B., Contreras-Trujillo H., Fathman J.W., Fernhoff N.B., Seita J., Inlay M.A., Weiskopf K., Miyanishi M., Weissman I.L. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl. Acad. Sci. USA 2013, 110:11103-11108.